Search
GLB-006
go.drugbank.com/drugs/DB32799ExperimentalGLB-006 is a molecular glue degrader targeting NEK7.[L56125, L56126]
APT20TTMG
go.drugbank.com/drugs/DB32869ExperimentalAPT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.
RS5441
go.drugbank.com/drugs/DB33178ExperimentalRS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]
VV-14300
go.drugbank.com/drugs/DB33996ExperimentalVV-14300 is a biologic drug. VV-14300 is under investigation in clinical trial NCT07829302 (VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes).
VV-14299
go.drugbank.com/drugs/DB33997ExperimentalVV-14299 is a biologic drug. VV-14299 is under investigation in clinical trial NCT07829302 (VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes).
RXC008
go.drugbank.com/drugs/DB33985ExperimentalRXC008 is a small molecule drug. RXC008 is under investigation in clinical trial NCT07832435 (A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures).
Risperidone
go.drugbank.com/drugs/DB00734ApprovedInvestigationalRisperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. … [L12885] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets
Products: RISPERIDON AL 1MG, RISPERIDON AL 2MGNaftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum
International brands: A MeiRiluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalA glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.
Categories: Compounds used in a research, industrial, or household settingInternational brands: Xie Yi LiScopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]